Status:
RECRUITING
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Breast Cancer
Eligibility:
FEMALE
19+ years
Brief Summary
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and aft...
Eligibility Criteria
Inclusion
- Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study.
- Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.
- Those who need neoadjuvant chemotherapy as breast cancer patients
- Those who need adjuvant chemotherapy after breast cancer surgery
- Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion
- Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers.
- Those are diagnosed with secondary breast cancers.
- Those with Stage 0/1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.
Key Trial Info
Start Date :
July 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
1052 Patients enrolled
Trial Details
Trial ID
NCT06537752
Start Date
July 15 2024
End Date
October 1 2026
Last Update
September 12 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ang University Hospital
Seoul, South Korea, 06973
2
Uijeongbu Eulji Medical Center, Eulji University
Uijeongbu-si, South Korea, 11759